A Phase 2 interventional study of Milnacipran and Placebo in Fibromylagia, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University Hospital, Clermont-Ferrand · Phase 2, Interventional, and Treatment
Pickering G, Macian N, Delage N, Picard P, Cardot JM, Sickout-Arondo S, Giron F, Duale C, Pereira B, Marcaillou F. Milnacipran poorly modulates pain in patient…PubMed 30127596 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing milnacipran in Fibromyalgia — none open to participants now, none under way, none of them phase 3. Milnacipran · Fibromyalgia.
Among the 22 studies testing milnacipran in Fibromyalgia, this one is the 13th largest by enrollment, is the only one that started in 2013, is one of 4 in phase 2, and was the 20th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →None of the 22 studies testing milnacipran in Fibromyalgia is open now. The open studies under Fibromyalgia, anywhere →
Milnacipran: first FDA approval 2009 (SAVELLA). What it is approved for, and how studies give it, is on its page →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 9 · Phase 4 7
First in 2004; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 54 across the 22 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 22 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 4 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing milnacipran in Fibromyalgia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fibromyalgia affects 0.7 to 3.3% of the adult population and 7-10 times more women than men. In France, the prevalence is 1.6% according to a French study conducted in 2009 and published in 2011 by Serge Perrot et al.
The definition of fibromyalgia was recently amended with particular consideration of cognitive and somatic symptoms, factors not involved in the initial criteria of the ACR classification. Several factors are in favor of a malfunction of the central modulation of pain and poorer performance noxious inhibitory controls descendants (DNIC: diffuse noxious inhibitory controls) have been demonstrated. In fibromyalgia patients, the DNIC (diffuse noxious inhibitory controls) are altered with less pain inhibition than controls. Dysfunction of the central pain modulation is widely described in the literature and contributes to pain complained of fibromyalgia.
According to the Recommendations of the European League Against Rheumatism (EULAR) 2006, antidepressants have a genuine analgesic efficacy in controlled studies. Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR. A review included five double-blind studies on 4,000 participants who took 100 mg or 200 mg milnacipran or placebo over a period of 8 weeks to 24 weeks. A moderate response was obtained for 40% of participants treated for each dose of milnacipran on the criteria of "at least 30% pain relief" Impression and global change. Substantial improvement with milnacipran compared to placebo has been shown.
To date, the link between the weakening of DNIC in fibromyalgia and effectiveness of drug treatment has not been shown.
This study aims to assess the degree of impairment of DNIC in fibromyalgia patients may be predictive of the efficacy of milnacipran.
Visit 1 Inclusion of the patient, Clinical examination, Evaluation of pain, basal Pain and cognitive tests
Visit 2 (can be coupled with Visit 1 if necessary) Randomisation of the patient and allocation of the treatment for 1 month.
Phone contact Visit 2 +7 days, + 15 days, +21 days Follow-up of the compliance of the treatment and collection of adverse events.
Visit 3 (follow up at 1 month) Evaluation of pain, Pain and cognitive tests End of study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR
Drug: Milnacipran
placebo over a period of 8 weeks to 24 weeks
Drug: Placebo
100mg/day
Pain scores on the verbal numeric scale
Time frame: at T0 and T0+1 month
sensitivity and pain thresholds to a mechanical stimulus
Time frame: at T0 and T0+1 month
sensitivity and pain thresholds to a thermal stimulus
Time frame: at T0 and T0+1 month
scores on cognitive tests
Time frame: at T0 and T0+1 month
Adverse events record
Time frame: at T0 and T0+1 month
Ran from Apr 2013 to primary completion in Apr 2016, 35 months.
Of 24 phase 2 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 35 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Nov 2014 → Apr 2016 and completion Nov 2014 → Jun 2016.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Pickering G, Macian N, Delage N, Picard P, Cardot JM, Sickout-Arondo S, Giron F, Duale C, Pereira B, Marcaillou F. Milnacipran poorly modulates pain in patient…PubMed 30127596 ↗
Pickering G, Macian N, Delage N, Picard P, Cardot JM, Sickout-Arondo S, Giron F, Duale C, Pereira B, Marcaillou F. Milnacipran poorly modulates pain in patient…PubMed 30127596 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Milnacipran
University Hospital, Clermont-Ferrand →